Home
GSC Biological and Pharmaceutical Sciences
Peer-reviewed Journal | Impact factor 8.1 | ISSN: 2581-3250 | CAS Source Indexed | Crossref DOI

Main navigation

  • Home
    • Journal Information
    • Editorial Board Members
    • Reviewer Panel
    • Abstracting and Indexing
    • Journal Policies
    • Our CrossMark Policy
    • Publication Ethics
    • Issue in Progress
    • Current Issue
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Join Editorial Board
    • Join Reviewer Panel
  • Contact us
  • Downloads

Research and review articles are invited for publication in September 2026 - Vol. 36, Issue 3 

🌟 GSC Biological and Pharmaceutical Sciences (GSCBPS) 🌟

Low Publication Charges | Fast Editorial Processing | Crossref DOI Linking | Transparent Peer-Review Process

Publishing quality research in Biological Sciences, Pharmaceutical Sciences, Medicine, Healthcare and Allied Life Sciences.

e-ISSN: 2581-3250 | Impact Factor: 8.1 | Established: 2017 | Charges: USD 35 / INR 2100

📄 Submit Manuscript 👉 Author Guidelines 📚 Published Articles 

Emerging XBB variants in Vietnam show high affinity for hACE2

Breadcrumb

  • Home
  • Emerging XBB Variants In Vietnam Show High Affinity For HACE2
  • Emerging XBB variants in Vietnam show high affinity for hACE2

Quan Ke Thai 1, * and Phuoc Huynh 2

1 Faculty of Natural science Education, Saigon University, 273 An Duong Vuong, Ward 3, District 5, Ho Chi Minh City, Vietnam, 700000.
2 VNU HCMC University of Science, 227 Nguyen Van Cu, Ward 4 District 5, Ho Chi Minh city, Vietnam, 700000
 
Research Article
GSC Biological and Pharmaceutical Sciences, 2023, 23(03), 231–236.
Article DOI: 10.30574/gscbps.2023.23.3.0256
DOI url: https://doi.org/10.30574/gscbps.2023.23.3.0256
Received on 19 May 2023; revised on 27 June 2023; accepted on 29 June 2023
Since the beginning of 2022, the Omicron variant of the SARS-CoV-2 virus responsible for the COVID-19 pandemic has been the dominant variant. Numerous subvariants of Omicron have been identified, including BA.2.75, BA.4, and BA.5, which are classified as Variants of Concern (VOCs) due to their potential to cause severe illness. Additionally, an emerging variant called XBB has recently caused outbreaks and is believed to be highly lethal. To better understand the XBB variant, we compared the variation in the S protein to that of the other variants. Our initial findings indicate that the XBB variant has spread in Vietnam and carries unique nucleotide changes in the S gene. Specifically, we observed two mutations, G22317T (G252V) and C23123T (P521S), that have resulted in a new subvariant called XBB.1 on the phylogenetic tree. Our analysis also suggests that the XBB variant has a high affinity for hACE2, as indicated by an increase in the interface's number of residues and van der Waals energy. We found that XBB has conserved mutations in RBD that enhance its binding affinity for hACE2. In this report, we noted the mutation V83A, H146Q, and G252V in the NTD increased the binding free energy of the XBB spike protein in the complex with hACE2.
SARS-CoV-2; Omicron; XBB variant; Spike protein; Spike gene; Vietnam.
https://gscbps.gsconlinepress.com/sites/default/files/fulltext_pdf/GSCBPS-2023-…

Preview Article PDF

Quan Ke Thai and Phuoc Huynh. Emerging XBB variants in Vietnam show high affinity for hACE2. GSC Biological and Pharmaceutical Sciences, 2023, 23(3), 231-236. Article DOI: https://doi.org/10.30574/gscbps.2023.23.3.0256


📝 Copyright, Licensing and Permissions: © Copyright Author(s). This article is published under the 🌐 Creative Commons Attribution 4.0 International License (CC BY 4.0) , which permits unrestricted use, distribution, adaptation, and reproduction in any medium, provided the original author(s) and source are properly credited, a link to the license is provided, and any changes made are indicated.


⚠️ Disclaimer: The statements, opinions, interpretations, and data presented in this publication are solely those of the individual author(s). GSC Biological and Pharmaceutical Sciences (GSCBPS), the editors, reviewers, editorial board, and publisher disclaim responsibility for any errors, omissions, or consequences arising from the use of the information contained in this article.


🏆 Get Publication Certificate 📄 Download Letter of Acceptance 🔗 Verify Crossref DOI 📘 View Issue Cover Page 👨‍🔬 Editorial Board 📑 Table of Contents 

🚀 Publish Your Research in International Peer Reviewed Open Access Journal - GSC Biological and Pharmaceutical Sciences (GSCBPS)

Submit your manuscripts from Biological Sciences, Pharmaceutical Sciences, Medicine, Healthcare, Biotechnology and Allied Life Sciences etc.

🌍 International Journal   |   👨‍🔬 Transparent Peer Review Process   |   🌐 Open Access Publishing   |   🔗 Crossref DOI 
⚡ Fast Editorial Processing   |   💰 Low Publication Charges

📝 Submit Your Manuscript 📘 Author Guidelines 💰 Publication Charges 

✅ No Submission Fee •  📜 Free Publication Certificate • 🌍 Global Visibility

⭐ Popular Pages


  • 🌍 International Journal
  • 🌐 Open Access Journal
  • 👨‍⚖️ Peer-Reviewed Journal
  • 💰 Low APC Journal
  • 🚀 Fast Publication Journal
  • ⚡ Fast-Track Peer-Review
  • 🔗 Crossref DOI Journal
  • 📖 Refereed Journal
  • 📈 High Impact Journal
  • 🧬 International Biology Journal
  • 💊 International Pharmacy Journal
  • 📝 Publish Research Paper

✍️ Author Resources


  • 📝 Publish Research Paper
  • 📖 Author Guidelines
  • 🎯 Aims and Scope
  • 💳 Article Processing Charges
  • 📤 Submit Manuscript
  • 📄 Cover Letter
  • ✍️ Author Declaration Form
  • 📄Track Manuscript Status
  • 📜 Get Publication Certificate
  • 📚 Journal Past Issue Archive
  • 🔎 Journal Indexing

⚖️ Journal Policies


  • ⚖️ Publication Ethics
  • 🛡️ Plagiarism Policy
  • 👨‍🔬 Peer Review Policy
  • 👨‍⚖️ Peer Review Process
  • 📖 Open Access Publishing
  • 📜 Copyright & Licensing
  • 🔗Author Self-Archiving Policy
  • 👥 Authorship Policy
  • 📊 Data Sharing Policy
  • 🤖 AI Usage Policy

Copyright © 2026 GSC Biological and Pharmaceutical Sciences - All rights reserved

Developed & Designed by VS Infosolution